Therapeutic potential of new hydrogen sulfide-releasing hybrids

Expert Rev Clin Pharmacol. 2011 Jan;4(1):109-21. doi: 10.1586/ecp.10.122.


A new class of hydrogen sulfide (H(2)S)-donating hybrids combined with pharmacologically active compounds is presented in this article. The pharmacological profiles of some hybrid lead compounds in the areas of inflammation, H(2)S-donating diclofenac (ACS 15); cardiovascular, H(2)S-donating aspirin (ACS 14); urology, H(2)S-donating sildenafil (ACS 6); and neurodegenerative, H(2)S-donating latanoprost (ACS 67) for glaucoma treatment and H(2)S-donating levodopa (ACS 84) for Parkinson's disease, are described. The new H(2)S-releasing hybrids demonstrate remarkable improvement in activity and tolerability as compared with the related parent compounds, suggesting an active pharmacological role for H(2)S. Finally the mechanism(s) of action of glutathione-dependent and independent, and of gas (H(2)S) release (spontaneous or enzymatic) and its implications for clinical pharmacology perspectives will be also discussed.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
  • Aspirin / administration & dosage
  • Diclofenac / administration & dosage
  • Humans
  • Hydrogen Sulfide / administration & dosage*
  • Hydrogen Sulfide / metabolism*
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Latanoprost
  • Levodopa / administration & dosage
  • Prodrugs / administration & dosage
  • Prostaglandins F, Synthetic / administration & dosage


  • Anti-Inflammatory Agents, Non-Steroidal
  • Prodrugs
  • Prostaglandins F, Synthetic
  • Diclofenac
  • Levodopa
  • Latanoprost
  • Aspirin
  • Hydrogen Sulfide